Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

NICE Upholds GlaxoSmithKline Appeal For Advanced Breast Cancer Treatment, Tyverb(R)(lapatinib)
The National Institute for Health and Clinical Excellence (NICE) announced that, following GlaxoSmithKline"s (GSK) appeal, it will reconsider the submission for Tyverb (lapatinib), a treatment for an aggressive form of advanced breast cancer (ErbB2-positive).1 GSK is pleased that NICE"s appeal panel agreed that the draft negative guidance should be reviewed, providing fresh hope for up to 2,000 women in the UK who could benefit from this effective treatment on the NHS.
generic viagra online
Ultrasound Outperforms Symptom Analysis In Detecting Ovarian Cancer
Doctors at the University of Kentucky Chandler Medical Center-Markey Cancer Center compared symptom analysis to ultrasound in predicting ovarian cancer. They selected 272 women participating in annual trans-vaginal screening (TVS) from 31,748 women enrolled in a free screening project at the university, comparing symptom results to ultrasound and surgical pathology findings.
News of the day
What Is Astigmatism? What Causes Astigmatism?
Astigmatism is an eye condition with blurred vision as its main symptom. The front surface of the eye (cornea) of a person with astigmatism is not curved properly - the curve is irregular - usually one half is flatter than the other - sometimes one area is steeper than it should be.
Health Insurance

Multidisciplinary Cancer Congress

ECCO 15 - ESMO 34 will take place at the ICC Berlin - Internationales Congress Centrum, Messedamm 22, D-14055 Berlin, Germany (http://www.icc-berlin.de) from Sunday 20 September to Thursday 24 September 2009. ECCO 15 - ESMO 34 will build on the success of the previous ECCO (European Cancer Conference) and ESMO (European Society for Medical Oncology) conferences. It provides a unique European forum for presentations of cutting-edge research from experimental and clinical oncologists, epidemiologists and cancer nurses. Over 15,000 scientists, doctors, nurses, patients, carers and industry representatives are expected to attend. More than 100 experts in different cancer fields have developed a wide-ranging and exciting congress programme, with large numbers of reports of translational research and first reports from high quality phase III clinical trials. In addition, for the first time there will be an "oncopolicy" track; this has been introduced to help inform European policy on cancer and to ensure its place at the top of the EU health and research policy agenda. Mary Rice ECCO-the European CanCer Organisation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009